Spero Therapeutics (NASDAQ:SPRO) has been assigned a $30.00 target price by research analysts at Oppenheimer in a research report issued on Monday. The firm presently has a “buy” rating on the stock. Oppenheimer’s price target points to a potential upside of 180.37% from the company’s previous close.

A number of other brokerages also recently commented on SPRO. Bank of America began coverage on Spero Therapeutics in a report on Monday, November 27th. They issued a “neutral” rating for the company. Stifel Nicolaus began coverage on Spero Therapeutics in a report on Monday, November 27th. They issued a “buy” rating and a $26.00 price target for the company. Finally, Cowen began coverage on Spero Therapeutics in a report on Monday, November 27th. They issued an “outperform” rating for the company.

Shares of Spero Therapeutics (NASDAQ:SPRO) opened at $10.70 on Monday. Spero Therapeutics has a 12 month low of $9.84 and a 12 month high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.20 million. analysts expect that Spero Therapeutics will post -6.35 EPS for the current fiscal year.

In other news, CFO Joel Sendek bought 5,000 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The shares were bought at an average price of $14.00 per share, with a total value of $70,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Plc Glaxosmithkline bought 428,571 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here. Insiders purchased 649,356 shares of company stock valued at $9,090,984 in the last three months.

TRADEMARK VIOLATION WARNING: “Spero Therapeutics (SPRO) Given a $30.00 Price Target by Oppenheimer Analysts” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/spero-therapeutics-spro-given-a-30-00-price-target-by-oppenheimer-analysts/1773905.html.

About Spero Therapeutics

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.